Profile of omalizumab in the treatment of chronic spontaneous urticaria
Labrador Horrillo, Moises (Hospital Universitari Vall d'Hebron)
Ferrer, Marta (Clínica Universidad de Navarra)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2015
Resum:	Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for the treatment of both adult and pediatric (children; >6-year-old) patients. In addition, in recent, well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy with subcutaneous omalizumab significantly reduced the severity of itching, and the number and size of hives, and increased patients' health-related QoL and the proportion of days free from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite background therapy with H1 antihistamines. In this review, we cover the following points: epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and finally, we focus on omalizumab in the treatment of CSU including the pharmacokinetic properties and mechanism of action, and use in pregnant women, nursing infants, and children.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Matèria:	Omalizumab ; Chronic spontaneous urticaria ; Antihistamines ; Subcutaneous administration ; Add-on therapy
Publicat a:	Drug Design, Development and Therapy, Vol. 9 (august 2015) , p. 4909-4915, ISSN 1177-8881

DOI: 10.2147/DDDT.S56004
PMID: 26346472

7 p, 216.6 KB

El registre apareix a les col·leccions:
Articles > Articles publicats